A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex®) with intramuscular formestane in postmenopausal women with advanced breast cancer

Annals of Oncology

Volumn 10, Issue 10, 1999, Pages 1219-1225

  Vorobiof, D A ^a   Kleeberg, U R ^b   Perez Carrion, R ^c   Dodwell, D J ^d   Robertson, J F R ^e   Calvo, L ^f   Dowsett, M ^g   Clack, G ^h  

^a Sandton Oncology Centre   (South Africa)

^b Haematology/Oncology Clinic   (Germany)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

^e NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^f Hospital Juan Canatejo   (Spain)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

^h ASTRAZENECA   (United Kingdom)

Author keywords

Anastrozole; Arimidex ; Aromatase inhibitor; Breast cancer; Formestane; Oestradiol; Tolerability

Indexed keywords

ANASTROZOLE; ESTRADIOL; ESTROGEN; ESTRONE; ESTRONE SULFATE; FORMESTANE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; ENDOCRINE FUNCTION; FEMALE; HEADACHE; HORMONAL THERAPY; HORMONE INHIBITION; HOT FLUSH; HUMAN; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SWEATING; VOMITING;

EID: 0032738439     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008308609325     Document Type: Article

References (18)

1. Gelber RD, Goldhirsch A, Coates AS. Adjuvant therapy for breast cancer. Understanding the overview. J Clin Oncol 1993; 11 (3): 580-5.
2. Brodie AMH, Njar VCO. Aromatase inhibitors in advanced breast cancer: Mechanism of action and clinical implications. J Steroid Biochem Mol Biol 1998; 66 (1-2): 1-10.
3. Roseman BJ, Buzdar AU, Singletary SE. Use of aromatase inhibitors in postmenopausal women with advanced breast cancer. J Surg Oncol 1997; 66 (3): 215-20.
4. Johannessen DC, Lønning PE. Aromatase inhibitors in malignant diseases of aging. Clin Pharmacol 1992; 2 (6): 530-45.
5. Coombes RC, Hughes SWM, Dowsett M. 4-hydroxyandrostenedione: A new treatment for postmenopausal patients with breast cancer. Eur J Cancer 1992; 28A (12): 1941-5.
6. Geisler J, King N, Dowsett M et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996; 74 (8): 1286-91.
7. Dukes M, Edwards PN, Large M et al. The preclinical pharmacology of 'Arimidex' (Anastrozole; ZD1033) - a potent selective aromatase inhibitor. J Steroid Biochem Mol Biol 1996; 58 (4): 439-45.
8. Yates RA, Dowsett M, Fisher GV et al. Arimidex (ZD1033): A selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 1996; 73 (4): 543-8.
9. Plourde PV, Dyroff M, Dukes M. Arimidex®: A potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 1994; 30(1): 103-11.
10. Buzdar AU, Jonat W, Howell A et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 1998; 83 (8): 1142-52.
11. Dowsett M, Goss PE, Powles TJ et al. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: Optimization of therapeutic dose and route. Cancer Res 1987; 47 (7): 1957-61.
12. Jones AL, MacNeill F, Jacobs S et al. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur J Cancer 1992; 28 (10): 1712-6.
13. Dowsett M, Doody D, Miall S et al. Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer. Breast Cancer Res Treat 1999; 56 (1): 25-34.
14. Hayward JL, Carbone PP, Heuson J-C et al. Assessment of response to therapy in advanced breast cancer. Cancer 1977; 39: 1289-94.
15. Dombernowsky P, Smith I, Falkson G et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16 (2): 453-61.
16. Buzdar AU, Smith R, Vogel C et al. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast cancer. Results of two randomized double-blind controlled multi-institutional trials. Cancer 1996; 77 (12): 2503-13.
17. Murray R, Van Zyl J, Gudgeon A et al. Rivizor™ versus amino-glutethimide in the second-line treatment of advanced postmenopausal breast cancer. Ann Oncol 1996; 7 (Suppl 5): 18 (Abstr 800).
18. Piccart M, Roy JA. Phase II studies with Rivizor® (Vorozole) in advanced breast cancer. Eur J Cancer 1996; 32A (Suppl 2): 51 (Abstr pp. 8-15).